QLS32015

DRUG4 trials

Sponsors

Qilu Pharmaceutical Co., Ltd., Institute of Hematology & Blood Diseases Hospital, China

Conditions

Relapsed or Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma (RRMM)

Early Phase 1

A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Not yet recruitingNCT07185477

Institute of Hematology & Blood Diseases Hospital, ChinaRelapsed/Refractory Multiple Myeloma (RRMM)

Start: 2025-09-15End: 2028-05-31Target: 20Updated: 2025-09-22

Phase 1

A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

Qilu Pharmaceutical Co., Ltd.Relapsed or Refractory Multiple Myeloma

Start: 2023-06-30End: 2025-08-31Target: 100Updated: 2023-06-27

Phase 2

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

RecruitingNCT07018050

Qilu Pharmaceutical Co., Ltd.Relapsed or Refractory Multiple Myeloma

Start: 2025-09-12End: 2028-07-01Target: 160Updated: 2026-06-08

Phase 3

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

RecruitingNCT07138209

Qilu Pharmaceutical Co., Ltd.Relapsed or Refractory Multiple Myeloma

Start: 2025-11-07End: 2029-12-01Target: 228Updated: 2026-05-22

Related Papers

First-in-Human, Phase Ia, Dose Escalation, Monotherapy Study of QLS32015, a Novel GPRC5D×CD3 T-Cell Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood2024-11-053 citations